Evidence map›Paper›PMID 23645755›Full record

ArticleAnticancer research2013

Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas.

Joseph L Lasky, Eduard H Panosyan, Ashley Plant, Tom Davidson, William H Yong, Robert M Prins, Linda M Liau, Theodore B Moore

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Anticancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04911621 (Adjuvant Dendritic Cell Immunotherapy Complementing Conventional Therapy for Pediatric Patients With High-grade Glioma and Diffuse Intrinsic Pontine Glioma), which is not on this map. Cited by 48 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04911621 phase1 / phase2completednot on this mapstarted 2021, after this paper: background citation

Adjuvant Dendritic Cell Immunotherapy Complementing Conventional Therapy for Pediatric Patients With High-grade Glioma and Diffuse Intrinsic Pontine Glioma

TypeinterventionalSponsorUniversity Hospital, AntwerpRan2021 to 2025Enrolled10ConditionsHigh Grade Glioma, Diffuse Intrinsic Pontine GliomaArmsDendritic cell vaccination + temozolomide-based chemoradiation, Dendritic cell vaccination +- conventional next-line treatment
3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Tumour immune landscape of paediatric high-grade gliomas.Brain : a journal of neurology · 2021
    Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Joseph L LaskyDepartment of Pediatrics, Division of Pediatric Hematology/ Oncology, Harbor-UCLA Medical Center/LA Biomed, David Geffen School of Medicine UCLA, Torrance, CA 90502, USA. jlasky@labiomed.org
Eduard H Panosyan
Ashley Plant
Tom Davidson
William H Yong
Robert M Prins
Linda M Liau
Theodore B Moore
UCLA Medical Center · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
TUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gay M Crooks, David A. Nathanson · 1985 to 2026
$10.5M
UCLA Clinical Scientist Training in Cancer Gene MedicineK12CA076905 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ECONOMOU, JAMES S. · 1997 to 2007
$3.2M
NCATS NIH HHS UL1 TR000124NCI NIH HHS K12 CA076905NCI NIH HHS L40 CA130665NCI NIH HHS T32 CA009056
6 · The paper itself

Abstract

Immunotherapy has the potential to improve clinical outcomes with little toxicity for pediatric patients with brain tumors. We conducted a pilot feasibility study of tumor lysate-pulsed dendritic cell (DC) vaccination in pediatric patients (1 to 18 years old) with newly diagnosed or recurrent high-grade glioma (HGG). A total of nine DC vaccine doses, each containing 1 × 10(6) cells per dose were administered to three out of the seven originally enrolled patients. Toxicities were limited to mild side-effects, except in one case of elevated alkaline phosphatase, which resolved without clinical consequences. Two patients with primary lesions amongst the three vaccinated were alive at the time of writing, both without evidence of disease. Pre- and post-vaccination tumor samples from a patient with an anaplastic oligoastrocytoma that recurred failed to demonstrate immune cell infiltration by immunohistochemistry. Peripheral cytokine levels were evaluated in one patient following DC vaccination and demonstrated some changes in relation to vaccination. DC vaccine is tolerable and feasible with some limitations for pediatric patients with HGG. Dendritic cell based immunotherapy may provide some clinical benefit in pediatric patients with glioma, especially for patients with minimal residual disease, but further investigation of this modality is required.

Indexed as

ImmunotherapyAdolescentBrain NeoplasmsCancer VaccinesChildChild, PreschoolCytokinesDendritic CellsFeasibility StudiesFemaleGliomaHumansImmunoenzyme TechniquesInfantLeukapheresisMaleCancer VaccinesCytokinesdendritic cell vaccinehigh grade gliomaimmunotherapyPediatric neuro-oncology

Identifiers

PMID23645755
PMCPMC4018463
OpenAlexW1848890174

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.